Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review –
Description
Playback speed:
<button class="mdp-speaker--speed-button" aria-label="0.8x speed" title="0.8x speed" data-speed="0.8">0.8x</button>
<button class="mdp-speaker--speed-button" aria-label="1x speed" title="1x speed" data-speed="1">1x</button>
<button class="mdp-speaker--speed-button" aria-label="1.3x speed" title="1.3x speed" data-speed="1.3">1.3x</button>
<button class="mdp-speaker--speed-button" aria-label="1.6x speed" title="1.6x speed" data-speed="1.6">1.6x</button>
<button class="mdp-speaker--speed-button" aria-label="2x speed" title="2x speed" data-speed="2">2x</button>
Stephanie Santarriaga et al.
Schizophrenia Research.
2023.
Cognitive impairment is the strongest predictor of functional outcomes in schizophrenia and is hypothesized to result from synaptic dysfunction. However, targeting synaptic plasticity and cognitive deficits in patients remains a significant clinical challenge. A comprehensive understanding of synaptic plasticity and the molecular basis of learning and memory in a disease context can provide specific targets for the development of novel therapeutics targeting cognitive impairments in schizophrenia. Here, we describe the role of synaptic plasticity in cognition, summarize evidence for synaptic dysfunction in schizophrenia and demonstrate the use of patient derived induced-pluripotent stem cells for studying synaptic plasticity in vitro. Lastly, we discuss current advances and future technologies for bridging basic science research of synaptic dysfunction with clinical and translational research that can be used to predict treatment response and develop novel therapeutics.
Cognitive deficits; Schizophrenia; Synaptic plasticity; iPSCs.
United States
